Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Large ribosomal subunit protein mL53, mitochondrial (MRPL53)
- Target
- MRPL53
- Molecular classification
- Ribosomal protein, Mitochondrial large ribosomal subunit protein, Protein coding gene, Member of the thioredoxin-like superfamily (based on domain annotation)
01
Overview
MRPL53 encodes a protein that is a component of the large (39S) subunit of the mitochondrial ribosome in mammals. It is encoded by nuclear DNA and imported into mitochondria, where it participates in translating mitochondrial mRNA to synthesize core subunits of the electron transport chain. Unlike cytoplasmic ribosomes, the mitoribosome has a higher protein-to-rRNA ratio and lacks a 5S rRNA. MRPL53 is expressed across numerous tissues and is required for proper mitochondrial translation and energy production. Impairment of mitochondrial ribosomal subunits, including MRPL53, can result in decreased energy production and mitochondrial disease. However, MRPL53 itself is not recognized as a therapeutic target or used as a clinical biomarker.
- Other names
- MRPL53L53mtMRP-L53mL5339S ribosomal protein L53, mitochondrialL53MTmitochondrial large ribosomal subunit protein mL53
02
Mechanism of action
Not applicable. No known drugs are reported to target MRPL53.
03
Biological functions
Mitochondrial translation (protein synthesis within mitochondria)Structural component of the mitochondrial 39S ribosomal subunitContributes to biosynthesis of mitochondrial proteins, especially those implicated in the electron transport chain
04
Disease associations
Mutations in mitoribosomal proteins can cause mitochondrial diseases, particularly affecting energy-reliant organs. However, specific links of MRPL53 to named diseases are not readily established in current literature.Candidate gene for orofacial clefting based on expression studies
05
Safety considerations
None documented. As a structural mitochondrial ribosomal protein, MRPL53 is not targeted directly by current drugs, so typical therapeutic safety concerns do not apply.
06
Interacting drugs
None known or listed in current databases and literature. No drugs are reported to specifically interact with MRPL53.
07
Biomarkers
None established. MRPL53 is not known to be used for patient selection or efficacy monitoring in any therapeutic context.
Beyond the preview
Go deeper on Large ribosomal subunit protein mL53, mitochondrial (MRPL53).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Large ribosomal subunit protein mL53, mitochondrial (MRPL53).